Neuroleptic malignant syndrome: Two cases without muscle rigidity

Australian and New Zealand Journal of Psychiatry

Volumn 30, Issue 3, 1996, Pages 415-418

  Wong, Michael M C ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS; DISEASE SEVERITY; FEVER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MENTAL DISEASE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SYMPTOM; THERMOREGULATION;

EID: 0030054658     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679609065008     Document Type: Article

References (21)

1. Delay J. Deniker P Drug-induced extrapyramidal syndrome. in Visken PJ, Bruyn GW, eds. Handbook of clinical neurology. New York: Elsevier, 1968:248-266.
2. Gurrera RJ, Chang SS, Romero JA A comparision of diagnostic criteria for neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1992; 53:56-62.
3. Smego RA, Durack DT. The neuroleptic malignant syndrome. Archives of Internal Medicine 1982; 142:1183-1185.
4. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica 1986; 73:337-347.
5. Lavie CJ, Olmsted TR, Ventura HO. Neuroleptic malignant syndrome. An underdiagnosed reaction to neuroleptic agents? Postgraduate Medicine 1986; 80:171-178.
6. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 1986; 143:1587-1590.
7. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 1989; 146:717-725.
8. Caroff SN. The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 1982; 41:79-83.
9. Zubenko D, Pope HG. Management of a case of neuroleptic malignant syndrome with bromocriptine. American Journal of Psychiatry 1983; 140:1619-1620.
10. Sternberg DE Neuroleptic malignant syndrome: the pendulum swings. American Journal of Psychiatry 1986; 143:1273-1275.
11. Langstone JW, Forno LS The hypothalamus in Parkinson's disease. Annual of Neurology 1978; 3:129-133.
12. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenic role for dopamine receptor blockade? Neurology 1981; 31:132-137
13. Downey GP, Caroff S, Rosenberg H, Gerber JC, Heiman-Patterson TD, Aronson MD. Neuroleptic malignant syndrome. Patient with unique clinical and physiologic features. American Journal of Medicine 1984; 77:338-340.
14. Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985; 26:62-66.
15. Conlon P. The spectrum concept of neuroleptic toxicity. American Journal of Psychiatry 1986; 143:811.
16. Pope HG, Keck PE, McElory SL Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 1986; 143:1227-1233.
17. Guze BH, Baxter LR. Current concept: neuroleptic malignant syndrome. New England Journal of Medicine 1985; 313:163-166.
18. Burke RE, Fahn S, Mayeux R. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Neurology 1981; 31:1022-1026.
19. Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. American Journal of Psychiatry 1984; 141:796-797.
20. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. Journal of the American Medical Association 1985; 254:2792.
21. Fogel BS, Goldberg RJ. Neuroleptic malignant syndrome. New England Journal of Medicine 1985; 313:1292.